Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 7:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cancer Free Women Clear all
Recruiting No phase listed Observational

WellSpan-THRIVE Cancer QOL Study

NCT07433660
View directory record Official record
Conditions
Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative, Cancer (Solid Tumors), Cancer (With or Without Metastasis), Cancer - Ovarian, Cancer Abdomen, Cancer (Advanced Stage)
Interventions
Not listed
Lead sponsor
WellSpan Health
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Chambersburg, Pennsylvania • Ephrata, Pennsylvania • Gettysburg, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jun 25, 2026, 7:31 PM EDT
Completed Phase 3 Interventional Results available

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

NCT01007942
View directory record Official record
Conditions
HER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
everolimus, Placebo, vinorelbine, trastuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
569 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
43
States / cities
Tucson, Arizona • La Jolla, California • Greenwood Village, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Jun 25, 2026, 7:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Healthy Human Control Blood Collection for Validation of Biomarker Assay

NCT02302885
View directory record Official record
Conditions
Healthy
Interventions
Blood collection
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jun 25, 2026, 7:31 PM EDT
Not yet recruiting Phase 3 Interventional

STENT X: a Randomized Trial to Assess Stent-free Radical Cystectomy

NCT07655284
View directory record Official record
Conditions
Bladder Cancer Requiring Cystectomy, Ureteral Stents
Interventions
ureteral stents, no ureteral stent
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jun 25, 2026, 7:31 PM EDT
Recruiting Phase 3 Interventional

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

NCT03592472
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Pazopanib, Abexinostat, Placebo
Drug · Other
Lead sponsor
Xynomic Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
14
States / cities
Phoenix, Arizona • Sacramento, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Jun 25, 2026, 7:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

MRI Parenchymal Enhancement: A New Marker of Breast Cancer Risk

NCT01649661
View directory record Official record
Conditions
Cancer Free Women
Interventions
questionnaire
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
437 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jun 25, 2026, 7:31 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy

NCT01042795
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Sunitinib
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Jun 25, 2026, 7:31 PM EDT
Completed Not applicable Interventional Results available

Clinical Utility of a PCR Compared to Culture and Sensitivity Testing for the Management of cUTI in Adults.

NCT06996301
View directory record Official record
Conditions
Urinary Tract Infection Complicated, Urinary Tract Infection (cUTI), Urinary Tract Infection (Diagnosis)
Interventions
Treatment guided by the PCR results, Treatment guided by the C&S results
Diagnostic Test
Lead sponsor
Doc Lab Inc
Industry
Eligibility
18 Years and older
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
San Jose, California • Albany, Georgia • Evans, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jun 25, 2026, 7:31 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients

NCT00418574
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Abagovomab, Placebo
Biological
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
888 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
22
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Jun 25, 2026, 7:31 PM EDT
Completed No phase listed Observational

Correlation of Menstrual Cycle Phase at Time of Primary Surgery With 5-Year Disease-Free Survival in Women With Stage I or Stage II Breast Cancer

NCT00002762
View directory record Official record
Conditions
Breast Cancer, Perioperative/Postoperative Complications
Interventions
patient interviewing to obtain menstrual history, blood sampling
Behavioral · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
1,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2009
U.S. locations
52
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Jun 25, 2026, 7:31 PM EDT
Active, not recruiting No phase listed Observational

Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment

NCT05926024
View directory record Official record
Conditions
Breast Cancer
Interventions
Exercise Recall Patient Reported Outcomes, Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes, Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes, Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a), Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12), Patient Reported Outcomes PROMIS, Patient Reported Outcomes FACT-Endocrine Symptoms, Patient Reported Outcomes Penn Arthralgia Aging Survey, Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE), p16 tumor suppressor gene
Behavioral · Diagnostic Test
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jun 25, 2026, 7:31 PM EDT
Completed Phase 2 Interventional Results available

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

NCT01923168
View directory record Official record
Conditions
Breast Cancer
Interventions
alpelisib, buparlisib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Jun 25, 2026, 7:31 PM EDT
Recruiting No phase listed Observational

International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors

NCT05363657
View directory record Official record
Conditions
Kidney Cancer
Interventions
Partial Nephrectomy (PN), Radical Nephrectomy (RN), Ablation therapy (AT), Active Surveillance (AS)
Procedure · Diagnostic Test
Lead sponsor
Azienda Ospedaliero-Universitaria Careggi
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Jun 25, 2026, 7:31 PM EDT
Terminated Phase 2 Interventional Results available

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment

NCT01521143
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Cvac, Placebo
Biological
Lead sponsor
Prima BioMed Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Los Angeles, California • Boynton Beach, Florida • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Jun 25, 2026, 7:31 PM EDT
Recruiting Not applicable Interventional

IDENTIFY Study: Natural History of Maternal Neoplasia

NCT04049604
View directory record Official record
Conditions
Maternal Neoplasia
Interventions
NIPT
Device
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 100 Years · Female only
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jun 25, 2026, 7:31 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

NCT05366881
View directory record Official record
Conditions
Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
Interventions
Not listed
Lead sponsor
Adela, Inc
Industry
Eligibility
40 Years and older
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
17
States / cities
Duarte, California • Miami, Florida • Gainesville, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jun 25, 2026, 7:31 PM EDT
Recruiting Phase 2 Interventional

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

NCT07322263
View directory record Official record
Conditions
Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS), High-Grade Papillary Bladder Tumors, BCG-Unresponsive Bladder Cancer, Ta Stage Bladder Cancer, T1 Stage Bladder Cancer, BCG-Refractory Bladder Cancer, High-Risk NMIBC, Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)
Interventions
Intravesical Gemcitabine and Docetaxel
Drug
Lead sponsor
Michael A. O'Donnell
Other
Eligibility
18 Years to 99 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jun 25, 2026, 7:31 PM EDT
Active, not recruiting Not applicable Interventional

Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer

NCT03289195
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI Biopsy
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jun 25, 2026, 7:31 PM EDT
Completed Phase 2 Interventional Results available

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

NCT00857545
View directory record Official record
Conditions
Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions
Laboratory Biomarker Analysis, Polyvalent Antigen-KLH Conjugate Vaccine, Saponin-based Immunoadjuvant OBI-821
Other · Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
46
States / cities
Mobile, Alabama • Orange, California • Palo Alto, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Jun 25, 2026, 7:31 PM EDT
Terminated Phase 2 Interventional Results available

IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery

NCT03029611
View directory record Official record
Conditions
Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions
Carboplatin, Gynecological Surgical Procedure, Laboratory Biomarker Analysis, Paclitaxel, pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine
Drug · Procedure · Other + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Jun 25, 2026, 7:31 PM EDT
Withdrawn Phase 4 Interventional

A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.

NCT06390111
View directory record Official record
Conditions
Bladder Cancer, Ta/T1, CIS
Interventions
nadofaragene firadenovec
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Little Rock, Arkansas • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Jun 25, 2026, 7:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer

NCT04883827
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Blood collection, Urine collection
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Jun 25, 2026, 7:31 PM EDT
Not listed Phase 3 Interventional Results available

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

NCT00382070
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Placebo
Drug · Other
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
3,966 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2025
U.S. locations
777
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 523 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Jun 25, 2026, 7:31 PM EDT